Posted by Reuters: Business News on July 28, 2011
PARIS (Reuters) – French drugmaker Sanofi raised its earnings forecast for 2011 now that Genzyme is part of its business, but said the U.S. biotech would likely miss its first milestone fee due to supply constraints of one of its key drugs.
Posted by Reuters: Business News on February 16, 2011
PARIS (Reuters) – French drugmaker Sanofi-Aventis SA clinched its long-sought deal for Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech…
Posted by Reuters: Business News on
NEW YORK (Reuters) – U.S. stocks rose on Wednesday after estimate-beating results from technology bellwether Dell and a deal for Sanofi-Aventis to buy Genzyme for $20.1 billion in cash.
Posted by Reuters: Business News on
NEW YORK (Reuters) – Stock index futures rose on Wednesday after estimate-beating results from Dell and a deal for Sanofi-Aventis to buy Genzyme for $20.1 billion in cash.
Posted by Reuters: Business News on
PARIS (Reuters) – French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs, the…
Posted by Reuters: Business News on
PARIS (Reuters) – French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs, the…
Posted by Reuters: Business News on
PARIS (Reuters) – French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp for $20.1 billion in cash, plus payments tied to the success of the U.S. biotech group’s drugs, the companies said on…
Posted by Reuters: Business News on
BOSTON/PHILADELPHIA (Reuters) – Sanofi-Aventis SA has reached an agreement in principle to buy Genzyme Corp for about $19 billion in cash plus future payments based on the performance of an…
Posted by Reuters: Business News on February 9, 2011
PARIS (Reuters) – Sanofi-Aventis reported progress in talks to buy U.S. biotech Genzyme and predicted 5-10 percent lower earnings in 2011, underscoring the French drugmaker’s need to find new sources…
Posted by Reuters: Business News on February 7, 2011
PARIS/BOSTON (Reuters) – France’s Sanofi-Aventis was closing in on a roughly $20 billion deal to buy U.S. biotech group Genzyme while pausing to take a final look at the books, sources familiar with…
